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Abstract The aim of this study was to evaluate, using a rat
model of balloon angioplasty, whether prostaglandin (PG) J2
and 2-cyclopenten-1-one are able to reduce restenosis. We found
that both PGJ2 and 2-cyclopenten-1-one, administered by local
application on carotid arteries, caused a dose-dependent inhibi-
tion of neointimal formation. Furthermore, both agents pre-
vented vascular negative remodeling. The e¡ect of these com-
pounds on restenosis was correlated with an inhibition of nuclear
factor-UB (NF-UB) activation as well as of intercellular adhe-
sion molecule-1 (ICAM-1) protein expression in injured carotid
arteries of control animals. Our results show that cyclopente-
none PGs and their derivatives reduce restenosis and may have
therapeutic relevance for the prevention of human restenosis.
- 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Percutaneous transluminal coronary angioplasty (PTCA) is
a widely used technique in the therapy of coronary artery
stenosis where the occluded segment is dilated by in£ating
an angioplasty balloon catheter. Despite a primary success
rate greater than 90%, the long-term e⁄cacy of this procedure
continues to be compromised by the re-narrowing of the ves-
sel, a phenomenon known as restenosis, which a¡ects 30^40%
of patients [1,2]. Restenosis was originally considered due to
an exaggeration of the normal reparative processes after bal-
loon-induced vascular injury leading to the migration of vas-
cular smooth muscle cells (VSMCs) from the media across the
internal elastic lamina (IEL) to form a new intimal layer or
‘neointima’ followed by replication of VSMCs within the neo-
intima [3^5]. Despite extensive characterization of the mech-
anisms underlying intimal hyperplasia, experimental strategies
to inhibit neointimal formation have generally failed to pre-
vent restenosis in clinical practice probably because other pro-
cesses (e.g. vascular remodeling) are involved [6]. Remodeling
refers to geometric redistribution of cells and matrix indepen-
dent of net change in wall mass or cross-sectional area. Thus,
cells and matrix reorganize either to increase wall diameter,
while decreasing wall thickness (positive remodeling) or to
decrease wall diameter, while increasing wall thickness (neg-
ative remodeling) [7]. Actually restenosis after balloon angio-
plasty is considered primarily due to negative vascular remod-
eling and only partially to VSMC proliferation [8]. Negative
vascular remodeling is a complex and poorly understood pro-
cess that involves alteration in the balance between cell pro-
liferation and apoptosis [9], matrix protein production and
degradation [10] as well as hemodynamic changing in blood
£ow [11,12] that cause a decrease of vessel diameter and lu-
men area. The exact mechanism of arterial neointimal thick-
ening remains to be understood and may involve growth fac-
tors, vasoactive agents, cytokines and adhesion molecules.
Most of these factors are regulated at transcriptional level
by nuclear factor-UB (NF-UB). Activation of NF-UB has
been found to occur also in balloon-injured rat carotid ar-
teries and has been associated with neointima formation and
expression of NF-UB-regulated genes such as cytokines,
growth factors and cell adhesion molecules, including inter-
cellular adhesion molecule-1 (ICAM-1) [13^15].
NF-UB is normally found in the cytoplasm of unstimulated
cells as an inactive complex, whose predominant form is a
heterodimer composed of p50 and p65 (Rel A) subunits,
bound to inhibitory proteins of the I-UB family, usually
I-UB-K [16]. NF-UB is activated in response to a variety of
pathogenic stimuli, including in£ammatory cytokines, endo-
toxins and oxidative stress. Several stimuli activate NF-UB
by augmenting the activity of the I-UB kinase (IKK) complex,
that phosphorylates I-UBs at sites that trigger their ubiquiti-
nation and proteasome-mediated degradation [17,18]. Freed
NF-UB dimers translocate to the nucleus where they bind to
speci¢c B elements and activate transcription of a variety of
genes encoding adhesion molecules, in£ammatory and chemo-
tactic cytokines, cytokine receptors, and enzymes that produce
in£ammatory mediators most of which are involved in devel-
opment of restenosis [18,19]. Thus NF-UB seems to be an
interesting therapeutic target for the development of mole-
cules able to inhibit restenosis.
0014-5793 / 03 / $22.00 J 2003 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
doi:10.1016/S0014-5793(03)00873-1
*Corresponding author. Fax: (39)-81-678 403.
E-mail address: ialenti@unina.it (A. Ialenti).
Abbreviations: cyPG, cyclopentenone prostaglandin; EMSA, electro-
phoretic mobility shift assay; IKK, I-UB kinase; ICAM-1, intercellu-
lar adhesion molecule-1; IEL, internal elastic lamina; L-PDGS, lipo-
calin-type prostaglandin D synthase; NF-UB, nuclear factor-UB;
PTCA, percutaneous transluminal coronary angioplasty; PPARQ, per-
oxisome proliferator-activated receptor-Q ; VSMC, vascular smooth
muscle cell
FEBS 27572 24-9-03 Cyaan Magenta Geel Zwart
FEBS 27572 FEBS Letters 553 (2003) 21^27
Prostaglandins (PGs) are a class of naturally occurring cy-
clic 20-carbon fatty acids synthesized from arachidonic acid
which are involved in the regulation of various physiological
and pathological processes including cell proliferation and in-
£ammation [20,21]. The type A and J PGs, characterized by
the presence of a reactive K,L-unsaturated carbonyl group in
the cyclopentane ring (cyclopentenone PGs, cyPGs), exhibit a
wide array of biological activities, including antiproliferative
and anti-in£ammatory e¡ects [22]. It has been shown that
cyPGs are able to inhibit the phosphorylation and prevent
the degradation of the NF-UB inhibitor I-UB-K in human cells
and this inhibition is dependent on the presence of the cyclo-
pentenone ring structure itself, 2-cyclopenten-1-one [22^24].
In the present study, using a rat carotid artery injury model,
we show that local delivery of PGJ2 or of 2-cyclopenten-1-one
reduces restenosis. We also show that this e¡ect is associated
with the block of NF-UB activation in injured vessels and with
decreased expression of ICAM-1, a gene regulated by NF-UB,
in the rat carotid artery.
2. Materials and methods
2.1. Animals
Male Wistar rats (Harlan, Italy) weighing 280^300 g were used for
this study. Animals were housed in propylene cages with food and
water ad libitum. The light cycle was automatically controlled (on
07:00 h; o¡ 19:00 h) and the room temperature thermostatically
controlled to 22P 1‡C. Prior to the experiment animals were housed
in these conditions for 4^5 days to become acclimatized.
2.2. Balloon angioplasty
Animals were anesthetized with an intraperitoneal injection of ket-
amine (100 mg/kg) and xylazine (5 mg/kg). Experimental rat balloon
angioplasty of the right common carotid artery was performed ac-
cording to the procedure described by Indol¢ et al. [25]. 2-Cyclopent-
en-1-one (6.5, 13 and 26 Wg/site) and PGJ2 (25, 50 and 100 Wg/site)
were administered by local application on carotid arteries, after vas-
cular injury, by using a solution of F127 pluronic gels prepared as
described in [26]. Control animals received an equal volume of plu-
ronic gel (200 Wl). Some animals were subjected to anesthesia and
surgical procedure without balloon injury (sham-operated rats).
Rats were killed 14 days after vascular injury and carotid arteries
were removed and processed as described below.
2.3. Morphology
After 14 days from angioplasty animals were anesthetized as de-
scribed above and the carotid arteries were immediately removed and
¢xed in 10% bu¡ered formalin. Sections were cut (6 Wm thick) from
the approximate midportion of the artery and stained with hematox-
ylin and eosin to demarcate cell types. Both the circumference and the
cross-sectional area of external elastic lamina (EEL), IEL, lumen,
media and neointima were measured as described by Ialenti et al.
[27] by using an image analysis system (Qwin Lite 2.2, Leica).
2.4. Arterial remodeling
For each animal the ratio between EEL circumference of right
injured artery (EELCR) and of EEL of left non-injured artery
(EELCL) was calculated as arterial remodeling index (ARI1) as pre-
viously described [28]. The same ratio was calculated using EEL di-
mension as cross-sectional area (ARI2).
2.5. Preparation of whole tissue extracts
All the extraction procedures were performed on ice with ice-cold
reagents. Separate carotid segments removed from rats treated as
described above after 14 days from angioplasty were frozen in liquid
nitrogen, immediately suspended in a volume of a high-salt extraction
bu¡er and incubated on ice for 15 min as previously described by
Ialenti et al. [27]. After centrifugation at 13 000Ug at 4‡C for 5 min,
the protein concentration in the supernatant was determined by the
Bio-Rad protein assay kit, and then it was aliquoted and stored at
380‡C.
2.6. Electrophoretic mobility shift assay (EMSA)
EMSA studies were performed on nuclear extracts as previously
described [27]. Brie£y, a double-stranded NF-UB consensus oligonu-
cleotide probe (5P-AGTTGAGGGGATTTTCCCAGGC-3P) was end-
labeled with [32P-Q]adenosine triphosphate (ATP). Tissue extracts
(12 Wg protein for each sample) were incubated with radiolabeled
oligonucleotides (2.5^5.0U104 counts per minute (cpm)) in 20 Wl re-
action bu¡er containing 2 Wg poly dI-dC, 10 mM Tris^HCl (pH 7.5),
100 mM NaCl, 1 mM ethylenediamine tetraacetic acid (EDTA), 1 mM
dithiothreitol, 1 Wg/Wl bovine serum albumin (BSA), 10% (v/v) glyc-
erol. To verify the speci¢city of protein^DNA complexes, in competi-
tion reactions nuclear extracts from injured carotid arteries were in-
cubated with radiolabeled NF-UB probe in the absence or the presence
of identical but unlabeled oligonucleotides (wild type, W.T. 50U),
mutated non-functional UB probe (Mut. 50U) or unlabeled oligonu-
cleotide containing the consensus sequence for Sp-1 (Sp-1 50U). Nu-
clear protein^oligonucleotide complexes were analyzed by gel electro-
phoresis. Gels were dried and autoradiographed with intensifying
screen at 380‡C for 20 h. Quantitative evaluation of NF-UB/UB com-
plex formation was determined by densitometric analysis of the X-ray
¢lms using a GS 700 Imaging Densitometer (Bio-Rad) with the Mo-
lecular Analyst program (IBM).
2.7. Immunohistochemical localization of ICAM-1
Carotid sections were depara⁄nized and permeabilized with 0.1%
Triton X-100 in phosphate-bu¡ered saline (PBS) for 10 min and re-
hydrated with PBS at room temperature for 45 min. Endogenous
peroxidase was quenched with 0.3% H2O2 in 60% methanol for
30 min. Non-speci¢c absorption was minimized by incubating the
section in 1% BSA in PBS for 40 min. Sections were subsequently
incubated overnight with primary anti-ICAM-1 (1:500 dilution). Con-
trols included bu¡er alone or non-speci¢c puri¢ed IgG. Speci¢c label-
ing was detected with biotin-conjugated speci¢c secondary antibody
and avidin-biotin peroxidase complex (Vectastain Elite ABC kit, Vec-
tor Laboratories).
2.8. Western blot analysis
The levels of ICAM-1 and L-actin were quanti¢ed in total extracts
of whole carotid arteries by Western blot analysis as previously de-
scribed [29]. Brie£y, equivalent amounts of protein (20 Wg) from each
sample were mixed with gel loading bu¡er (50 mM Tris/10% sodium
dodecyl sulfate (SDS)/10% glycerol/10% 2-mercaptoethanol/2 mg bro-
mophenol per ml) in a ratio of 1:1, boiled for 3 min, centrifuged at
10 000Ug for 10 min and electrophoresed in an 8% discontinuous
polyacrylamide minigel. The proteins were transferred onto nitrocel-
lulose membranes, according to the manufacturer’s instructions. The
membranes were saturated by incubation at 4‡C overnight with 10%
non-fat dry milk in PBS and then incubated with anti-ICAM-1 mono-
clonal antibody or anti-L-actin (1:1000) monoclonal antibody, for 2 h
at room temperature. The membranes were washed three times with
1% Triton X-100 in PBS and then incubated with anti-mouse immu-
noglobulins coupled to peroxidase (1:2000). The immune complexes
were visualized by the enhanced chemiluminescence method. Subse-
quently, the relative expression of the proteins was quanti¢ed by den-
sitometric scanning of the X-ray ¢lms with GS-700 Imaging Densi-
tometer (Bio-Rad, Milan, Italy) with the Molecular Analyst computer
program (IBM).
2.9. Statistic
Data are expressed as meansPS.E.M. of n rats. Statistical signi¢-
cance was calculated by one-way analysis of variance (ANOVA) and
Bonferroni-corrected P value for multiple comparisons. The level of
statistically signi¢cant di¡erence was de¢ned as P6 0.05.
2.10. Reagents
Bio-Rad protein assay kit and non-fat dry milk were from Bio-Rad,
Milan, Italy. Oligonucleotides were synthesized by Roche Biomol,
Milan, Italy. PBS was from Celbio (Milan, Italy). 2-Cyclopenten-1-
one was from Fluka (Milan, Italy). DL-dithiothreitol, phenylmethyl-
sulfonyl £uoride, soybean trypsin inhibitor, pepstatin A, leupeptin
and benzamidine were from Calbiochem (Milan, Italy). [32P-Q]ATP
was from ICN Biomedicals (Milan, Italy). Poly dI-dC was from
Boehringer-Mannheim (Milan, Italy). Anti-ICAM-1 was from DBA
(Milan, Italy). Anti-L-actin was from Sigma (Milan, Italy). All other
reagents were from Sigma (Milan, Italy).
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3. Results
3.1. E¡ect of 2-cyclopenten-1-one and PGJ2 on neointimal
proliferation
In sham-operated rats (n=5) not subjected to vascular in-
jury, no neointimal formation was observed. In balloon-in-
jured carotid arteries from control rats (n=12) the neointima
was increased to an area of 0.213P 0.008 mm2 (Fig. 1A).
Treatment with 2-cyclopenten-1-one at a dose of 6.5 Wg/site
(n=9) did not cause any alteration in the neointima area as
compared to the control group, while doses of 13 and 26 Wg/
site caused a dose-dependent inhibition of neointimal forma-
tion by 30% (n=8; P6 0.05) and 47% (n=9; P6 0.01), re-
spectively (Fig. 1A). Similar results were obtained with PGJ2
given at equimolar doses (25, 50 and 100 Wg/site). The neo-
intima area was decreased by 28 and 35% at doses of 50 and
100 Wg/site PGJ2 respectively, while it was unmodi¢ed when
this compound was given at a dose of 25 Wg/site (Fig. 1A).
The media area was not a¡ected by 2-cyclopenten-1-one and
PGJ2 at any of the doses tested (Fig. 1A). Representative
histological cross-sections of the carotid arteries are shown
in Fig. 1B.
3.2. E¡ect of 2-cyclopenten-1-one and PGJ2 on vascular
remodeling
Vascular negative remodeling was observed in the control
group after 14 days from angioplasty compared with sham-
operated animals (Table 1). Interestingly, treatment of rats
with both 2-cyclopenten-1-one and PGJ2 prevented vascular
negative remodeling. Thus, as shown in Table 1, 2-cyclopen-
ten-1-one signi¢cantly (P6 0.01) increased the ARI at highest
doses used (13 and 26 Wg/site). Similar results were obtained
with PGJ2 at doses of 50 and 100 Wg/site.
3.3. E¡ect of 2-cyclopenten-1-one and PGJ2 on NF-UB
activation
A low level of NF-UB/DNA binding activity was detected in
nuclear protein extracts from carotid arteries of sham-oper-
ated rats (n=3) (Fig. 2A). Conversely, a retarded band was
clearly shown in injured carotid arteries from control rats
(n=5). Treatment of rats with 6.5 Wg/site 2-cyclopenten-1-
one (n=5) or with 25 Wg/site PGJ2 (n=5) did not modify
NF-UB/DNA binding activity while either 13 Wg/site 2-cyclo-
penten-1-one (n=6) or 50 Wg/site PGJ2 (n=6) caused a sig-
ni¢cant (P6 0.05) inhibition of NF-UB activation by about
30% (Fig. 2A). Treatment of rats with 2-cyclopenten-1-one
(26 Wg/site; n=6) or with PGJ2 (100 Wg/site; n=6) resulted
in a complete inhibition of NF-UB activation in injured ar-
teries (Fig. 2A). The speci¢city of the NF-UB/DNA binding
complex was shown by the complete displacement of the NF-
UB/DNA binding in the presence of a 50-fold molar excess of
unlabeled NF-UB probe (W.T. 50U) in competition reactions
(Fig. 2B). In contrast, a 50-fold molar excess of unlabeled
mutated NF-UB probe (Mut. 50U) or of Sp-1 oligonucleotide
(Sp-1 50U) had no e¡ect on DNA binding activity.
Fig. 1. A: E¡ect of 2-cyclopenten-1-one (Cyclo; 6.5, 13, 26 Wg/site)
and PGJ2 (25, 50, 100 Wg/site) on media (open bars) and neointima
(solid bars) areas of injured carotid arteries. Results are expressed
as meanPS.E.M. *P6 0.05, **P6 0.01 vs. control group (C).
S= sham-operated rats. B: Photomicrographs showing the neointi-
mal formation in rat carotid arteries 14 days after balloon angio-
plasty. Representative cross-sections are from the carotid artery of
sham-operated rat, control rat subjected to balloon injury and rat
treated with 2-cyclopenten-1-one (Cyclo; 26 Wg/site) or PGJ2
(100 Wg/site) subjected to balloon injury.
Table 1
Arterial remodeling
Control 2-Cyclopenten-1-one (Wg/site) PGJ2 (Wg/site)
6.5 13 26 25 50 100
EELCR (mm) 2.611P 0.022* 2.607P 0.020* 2.658P0.040 2.672P 0.080 2.609P 0.020* 2.661P 0.040 2.668P 0.049
EELCL (mm) 2.668P 0.025 2.680P 0.026 2.684P0.022 2.690P 0.025 2.686P 0.025 2.689P 0.022 2.686P 0.023
ARI1 0.971P 0.022 0.972P 0.024 0.990P0.0253 0.993P 0.0153 0.971P 0.017 0.989P 0.0253 0.993P 0.0243
EELR area (mm2) 0.447P 0.006# 0.450P 0.010# 0.466P0.024 0.474P 0.020 0.445P 0.006# 0.468P 0.024 0.475P 0.023
EELL area (mm2) 0.475P 0.017 0.478P 0.015 0.474P0.015 0.476P 0.011 0.475P 0.017 0.473P 0.015 0.478P 0.010
ARI2 0.941P 0.020 0.941P 0.025 0.983P0.0223 0.996P 0.0203 0.936P 0.025 0.989P 0.0223 0.993P 0.0303
EELCR, EEL circumference of right injured carotid artery; EELCL, EEL circumference of left uninjured carotid artery; ARI1, EELCR/EELCL ;
EELR area, EEL area of right injured carotid artery; EELL area, EEL area of left uninjured carotid artery; ARI2, EELC area/EELL area.
*P6 0.01 vs. EELCL ; #P6 0.01 vs. EELL area; 3P6 0.01 vs. control.
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3.4. E¡ect of 2-cyclopenten-1-one and PGJ2 on ICAM-1
expression
Staining of carotid tissue sections obtained from sham-op-
erated rats with anti-ICAM-1 antibody showed a speci¢c
staining on endothelial cells and adventitia, demonstrating
that ICAM-1 is constitutively expressed (Fig. 3). In the con-
trol groups subjected to vascular injury the staining intensity
for ICAM-1 was substantially increased in the neointima
14 days after angioplasty as well as in VSMCs and adventitia
(Fig. 3). Analysis of carotid sections derived from rats treated
with either 2-cyclopenten-1-one (26 Wg/site) or PGJ2 (100 Wg/
site) revealed a down-regulation of ICAM-1 as compared to
the control group (Fig. 3). These results were con¢rmed by
Western blot analysis showing a signi¢cant level of ICAM-1
Fig. 2. A: Representative EMSA (upper panel) of NF-UB and densitometric analysis (lower panel) showing the e¡ect of 2-cyclopenten-1-one
(Cyclo; 6.5, 13 and 26 Wg/site) and PGJ2 (25, 50 and 100 Wg/site) on NF-UB/DNA binding activity in nuclear extracts of injured rat carotid ar-
teries 14 days after vascular injury. Results are expressed as meanPS.E.M. of three separate experiments. *P6 0.05, ***P6 0.01 vs. control
group (C). S= sham-operated rats. B: In competition reactions, nuclear extracts were incubated with radiolabeled NF-UB probe in the absence
or the presence of identical but unlabeled oligonucleotides (W.T. 50U), mutated non-functional UB probe (Mut. 50U) or unlabeled oligonu-
cleotide containing the consensus sequence for Sp-1 (Sp-1 50U). Results illustrated are from a single experiment and representative of three
separate experiments.
Fig. 3. Representative photomicrographs of sections of carotid arteries at 14 days after balloon angioplasty labeling for ICAM-1 (original mag-
ni¢cation: U250). Results illustrated are from a single experiment and are representative of three separate experiments. A: Sham-operated rat.
B: Control animal. C: 2-Cyclopenten-1-one (26 Wg/site). D: PGJ2 (100 Wg/site).
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protein expression in injured carotid arteries of control ani-
mals as compared to sham-operated rats (Fig. 4A). Treatment
of rats with 6.5 Wg/site 2-cyclopenten-1-one (n=5) or with
25 Wg/site PGJ2 (n=5) did not modify ICAM-1 expression
that was faintly but not signi¢cantly reduced by either 13 Wg/
site 2-cyclopenten-1-one (n=6) or 50 Wg/site PGJ2 (n=6)
(data not shown). Densitometric analysis showed that both
agents only at highest doses used signi¢cantly (P6 0.01) re-
duced ICAM-1 protein expression by about 40% (Fig. 4B).
4. Discussion
In this study we show that local delivery of either the cyclo-
pentenone prostanoid PGJ2 or 2-cyclopenten-1-one, the active
component of cyPGs, reduces restenosis by a¡ecting favorably
arterial remodeling as well as by inhibiting neointima forma-
tion. This e¡ect was associated with inhibition of NF-UB ac-
tivation that was triggered by vascular injury. As previously
shown in rat-injured carotids [14,27], the NF-UB complex ac-
tivated was found to be the heterodimer composed by the p50
and p65 subunits (data not shown). NF-UB inhibition resulted
in a reduced expression of ICAM-1, one of various adhesion
molecules that is activated via the NF-UB pathway and ex-
pressed in damaged vascular tissue [30]. In this study we ob-
served an increase of ICAM-1 expression in endothelial cells,
VSMCs and adventitia of injured carotids according to pre-
vious ¢ndings [31^33]. Several lines of evidence suggest that
ICAM-1 could play an important role in the restenotic pro-
cess. In fact, in a rabbit iliac artery balloon angioplasty model
it has been demonstrated that a reduced expression of ICAM-
1 was associated to a decreased restenosis [33]. Furthermore,
it has been shown in ICAM-1-de¢cient mice that neointimal
hyperplasia of vein bypass grafts was greatly reduced [31].
Although the importance of ICAM-1 in the mediation of
cell adhesion to endothelium has been established, little is
known about the role of ICAM-1 in VSMCs and adventitia.
The expression of ICAM-1 on VSMCs may be relevant to the
phenotypical change of VSMCs which is considered to be
essential to the migration and proliferation of these cells to
form neointimal layer [34]. On the other hand it has been
observed in a rat model of vascular remodeling that an in-
crease of ICAM-1 expression in adventitia contributes to the
in£ammatory in¢ltration leading to the perivascular ¢brosis,
an important event to wall shrinkage during pathological vas-
cular remodeling [32]. Our results show that treatment with
2-cyclopenten-1-one or PGJ2 actually inhibits important mo-
lecular events downstream of NF-UB activation leading to
prevention of neointima formation as well as of arterial re-
modeling.
NF-UB is an attractive therapeutic target for the pharma-
cological control of vascular response to injury. In fact, it has
been demonstrated that inhibition of NF-UB by an antisense
oligonucleotide to the p65 subunit of NF-UB as well as by the
antioxidant pyrrolidine dithiocarbamate, resulted in a reduc-
tion of neointima formation [13,27,35]. More recently it has
been shown in a porcine balloon-injured coronary artery mod-
el that neointimal formation was reduced by using a double-
stranded oligodeoxynucleotide with consensus NF-UB se-
quence demonstrating the feasibility of the ‘decoy’ strategy
against NF-UB in the treatment of restenosis after angioplasty
[36]. Consequently, the need for the development of e¡ective
NF-UB inhibitors with therapeutic e⁄cacy is widely recog-
nized. In this respect, cyPGs represent an interesting class of
molecules.
PGs of the J family, including PGJ2, v12-PGJ2 and 15-de-
oxy-v12;14-PGJ2 are non-enzymatic metabolites of PGD2
[37,38]. Recently it has been shown that the level of lipo-
calin-type PG D synthase (L-PDGS), which catalyzes the iso-
merization of PGH2 to PGD2 [39], was signi¢cantly increased
in patients undergoing PTCA but not su¡ering of subsequent
restenosis, whereas the level of L-PDGS remained unmodi¢ed
in patients who developed restenosis [40]. It may be hypothe-
sized that endogenous PGD2 generated by L-PDGS could
play a role in inhibiting the development of restenosis. The
fact that the local administration of the PGD2 metabolite
PGJ2 shown in this study is able to reduce neointima forma-
tion strengthens the hypothesis that generation of cyPGs in
the vessels could be part of a physiological mechanism to
Fig. 4. A: Representative Western blot analysis of the e¡ect of 2-cy-
clopenten-1-one (Cyclo; 26 Wg/site) and PGJ2 (100 Wg/site) on
ICAM-1 expression (upper panel) in carotid arteries. Equal loading
was con¢rmed by L-actin staining (lower panel). B: Densitometric
analysis of ICAM-1 expression. ICAM-1 levels in arbitrary units are
expressed as fold induction of ICAM-1 levels in sham-operated rats.
Results are expressed as meanPS.E.M. of three separate experi-
ments. **P6 0.01 vs. control group.
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prevent the development of restenosis. The protective e¡ect of
cyPGs may arise from di¡erent biological activities character-
istic of these molecules. CyPGs have in fact been considered
as part of an endogenous defence mechanism by which cells
preserve their homeostasis, and are known to possess cytopro-
tective properties via the activation of the heat shock tran-
scription factor type 1 (HSF-1) and the induction of the syn-
thesis of cytoprotective heat shock proteins [22]. Also, cyPGs
are known to exhibit antiproliferative properties in a number
of in vitro and in vivo tumor models [41]. It has also been
reported that PGJ2 prevents the proliferation of VSMCs, an
important component of neointimal thickening following ar-
terial balloon injury [42]. Moreover, cyPGs are characterized
by a potent anti-in£ammatory activity, due to their well-
known e¡ect as inhibitors of NF-UB activation during in£am-
mation and viral infection [43^46]. CyPGs have been shown
to act by blocking the phosphorylation and preventing the
degradation of NF-UB inhibitor I-UB-K [24]. The IKK was
identi¢ed as a selective molecular target for cyPGs, which
bind directly to the cysteine-179 residue in the activation
loop of the IKKL subunit. This e¡ect is dependent on the
presence of a reactive cyclopentenoic moiety [45].
Apart of their direct e¡ect as IKK inhibitors, the anti-in-
£ammatory e¡ect of cyPGs has also been attributed to their
ability to activate peroxisome proliferator-activated receptor-Q
(PPARQ), a nuclear receptor that interferes with the transcrip-
tional activity of NF-UB [44,47] and whose activation inhibits
VSMC proliferation [48]. Indeed, clinical observations indi-
cate that treatment with ¢brate PPARK activators lowers
the progression of atherosclerotic lesions [49^51] and that
the PPARQ agonist troglitazone decreases intimal thickness
in human carotid arteries [52]. However, it has been demon-
strated that the concentrations of selective PPARQ ligands
required to mimic the e¡ects of cyPGs are several orders of
magnitude higher than that required to activate PPARQ [47].
Furthermore, it has been observed that cyPGs inhibit NF-UB
activation in human cells expressing very low levels of PPARQ
[24].
CyPGs are characterized by the presence of a reactive K,L-
unsaturated carbonyl group in the cyclopentane ring (cyclo-
pentenone) which appears to be the key structure for their
e¡ects since it enables this portion of the molecule to form
Michael adducts with cellular nucleophiles, and covalently
bind to cysteine residues of proteins [53]. The cyclopentenone
structure itself (2-cyclopenten-1-one) has been shown to mimic
the e¡ect of cyclopentenone prostanoids in vitro, even though
at higher concentrations than the natural compounds [23]. We
have now shown that 2-cyclopenten-1-one also mimics the
e¡ect of the natural PGJ2 inhibiting NF-UB activation in
vivo, and that treatment with 2-cyclopenten-1-one is able to
reduce neointimal formation in balloon-injured rat carotid
arteries. It should be emphasized that 2-cyclopenten-1-one is
15^20 times less active than PGJ2 in inhibiting NF-UB in an in
vitro model in which human or murine cells are stimulated
with either the mitogen TPA or tumor necrosis factor-K (data
not shown). The similar activity of 2-cyclopenten-1-one and
PGJ2 in long-term experiments in vivo can be explained by the
fact that PGJ2 is known to be rapidly catabolized in vivo [37].
The di¡erence in c log P values between 2-cyclopenten-1-one
(0.03) and PGJ2 (2.97) may also be in£uential in terms of
dictating di¡erent rates of release of the two compounds
from their reservoirs.
These results open new perspectives in the design and de-
velopment of a novel class of molecules with potential activity
in the prevention of restenosis. Alternatively, these com-
pounds could also be useful in stent technology, in which
the coating of stents with these agents may help to delay
restenosis.
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